References
- Belvisi MG, Bundschuh DS, Stoeck M, et al. (2005). Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther 314:568–574
- Belvisi MG, Wicks SL, Battram CH, et al. (2001). Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 166:1975–1982
- Canalis E, Delany AM. (2002). Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci 966:73–81
- Chanoine F, Grenot C, Heidmann P, Junien JL. (1991). Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments. Drug Metab Dispos 19:546–553
- Christensson C, Thorén A, Lindberg B. (2008). Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects. Drug Saf 31:965–988
- De Martino MU, Alesci S, Chrousos GP, Kino T. (2004). Interaction of the glucocorticoid receptor and the chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII): implications for the actions of glucocorticoids on glucose, lipoprotein, and xenobiotic metabolism. Ann NY Acad Sci 1024:72–85
- Derendorf H, Nave R, Drollmann A, et al. (2006). Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 28:1042–1050
- Derendorf H. (2007). Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 47:782–789
- Eastell R, Hannon RA. (2008). Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 67:157–162
- Garcia-Marcos L, Ros-Lucas JA, Sanchez-Solis M. (2008). Inhaled corticosteroids in asthmatic children: are they as safe in infants and preschoolers as in older children? A review. Curr Drug Saf 3:35–45
- Herold MJ, McPherson KG, Reichardt HM. (2006). Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63:60–72
- Hong D, Chen HX, Ge RS, Li JC. (2008). The biological roles of extracellular and intracytoplasmic glucocorticoids in skeletal cells. J Steroid Biochem Mol Biol 111:164–170
- Korenblat PE. (2010). Ciclesonide and the treatment of asthma. Expert Opin Pharmacother 11:463–479
- McClaughlin F, Mackintosh J, Hayes BP, et al. (2002). Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. Bone 30:924–930
- McMaster A, Ray DW. (2007). Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects. Exp Physiol 92:299–309
- Miller SC, Bowman BM, Jee WSS. (1995). Available animal models of osteopenia – small and large. Bone 17:117S–123S
- Reid IR. (1997). Glucocorticoid osteoporosis – mechanisms and management. Eur J Endocrinol 137:209–217
- Shimo T, Takahara Y, Noguchi Y, et al. (1982). Comparative toxicity test of dexamethasone valerate (DV-17) and other steroid ointments in rats [in Japanese]. J Toxicol Sci 7 Suppl 1:15–33
- Ton FN, Gunawardene SC, Lee H, Neer RM. (2005). Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20:464–470
- Van Raalte DH, Ouwens DM, Diamant M. (2009). Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 39:81–93.
- Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. (1998). Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274–282
- Weldon D. (2009). The effects of corticosteroids on bone: osteonecrosis (avascular necrosis of the bone). Ann Allergy Asthma Immunol 103:91–97; quiz 97–100, 133